Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 662

Sort by

Sort Order Select

Journal Articles

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Antonio Cuneo, Lydia Scarfò, Gianluigi Reda, Marzia Varettoni, Francesca Maria Quaglia, Monia Marchetti, Lorenzo De Paoli, Francesca Re, Daniela Pietrasanta, Gian Matteo Rigolin, Lorella Orsucci, Adalberto Ibatici, Valter Gattei, Francesca R. Mauro, Livio Trentin, Luca Laurenti, Roberto Marasca, Robin Foà

Blood (2020) 136 (6): 763–766.

https://doi.org/10.1182/blood.2020006854

Published: 2020

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

Blood (2019) 134 (Supplement_1): 3855.

https://doi.org/10.1182/blood-2019-121954

Published: 2019

Journal Articles

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Serena Rosati, MD, Massimo Breccia, MD, Carmelo Gurnari, MD, Ida Carmosino, Emilia Scalzulli, MD, Enrico Montefusco, Salvatore Perrone, MD, Ombretta Annibali, Vincenza Martini, MD, Giulio Trapè, Malgorzata Monika Trawinska, MD, Clara Minotti, MD, Giuseppe Cimino, MD, Agostino Tafuri, MD, Giuseppe Avvisati, MD, Maria Teresa Voso, MD, Robin Foà, MD, Roberto Latagliata

Blood (2019) 134 (Supplement_1): 3845.

https://doi.org/10.1182/blood-2019-129216

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Blood (2019) 134 (Supplement_1): 4145.

https://doi.org/10.1182/blood-2019-126163

Published: 2019

Journal Articles

Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States

Mengyang Di, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 4012.

https://doi.org/10.1182/blood-2019-122361

Published: 2019

Journal Articles

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Michele Merli, MD, Benedetta Bianchi, MD, Lorenza Bertù, Andrea Ferrario, MD, Barbara Mora, Silvia Uccella, MD, Daniela Furlan, Maria Grazia Tibiletti, Simona Cattaneo, Fausto Sessa, Prof., Francesco Passamonti, Prof.

Blood (2019) 134 (Supplement_1): 4017.

https://doi.org/10.1182/blood-2019-130288

Published: 2019

Journal Articles

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Blood (2019) 134 (Supplement_1): 4153.

https://doi.org/10.1182/blood-2019-129335

Published: 2019

Journal Articles

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Mark Bishton, Pier Luigi Zinzani, MD PhD, Scott Marshall, Veronica Conteh, Alicia Rodríguez Fernández, SooKyoung Kim, Young Nam Lee

Blood (2019) 134 (Supplement_1): 4135.

https://doi.org/10.1182/blood-2019-121957

Published: 2019

Journal Articles

Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies

Ambar Farooqui, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Cassie Bacher, Jeanine Walenga, PhD, Ahmed Kouta, Walter Jeske, PhD, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 2446.

https://doi.org/10.1182/blood-2019-131825

Published: 2019

Journal Articles

Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model

Elisa Brilli, PhD, Michela Asperti, PhD, Annalisa Castagna, B.S., PhD, Claudio Cerchione, MD PhD, Domenico Girelli, MD, PhD, Maura Poli, PhD, Germano Tarantino

Blood (2019) 134 (Supplement_1): 2235.

https://doi.org/10.1182/blood-2019-122416

Published: 2019

Journal Articles

Altered Iron Parameters and Hepcidin Levels in a General Population: Lessons from the CHRIS Study

Fabiana Busti, MD PhD, Annalisa Castagna, B.S., PhD, Giacomo Marchi, MD, Oliviero Olivieri, MD, Peter Pramstaller, MD, Domenico Girelli, MD, PhD

Blood (2019) 134 (Supplement_1): 2239.

https://doi.org/10.1182/blood-2019-127098

Published: 2019

Journal Articles

Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks

Blood (2019) 134 (Supplement_1): 2747.

https://doi.org/10.1182/blood-2019-130210

Published: 2019

Journal Articles

Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Renato Bassan, MD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD PhD

Blood (2019) 134 (Supplement_1): 2624.

https://doi.org/10.1182/blood-2019-122931

Published: 2019

Journal Articles

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Alessandro Rambaldi, MD, Renato Bassan, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 2627.

https://doi.org/10.1182/blood-2019-122917

Published: 2019

Journal Articles

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Blood (2019) 134 (Supplement_1): 2931.

https://doi.org/10.1182/blood-2019-125052

Published: 2019

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Francesco Mazziotta, MD, Gabriele Buda, MD PhD, Nadia Cecconi, MD, Giulia Cervetti, MD, Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Matteo Pelosini, MD PhD, Edoardo Benedetti, MD, Francesco Caracciolo, MD, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2019) 134 (Supplement_1): 3254.

https://doi.org/10.1182/blood-2019-126118

Published: 2019

Journal Articles

ACUTE GRAFT Versus Host Disease 1990-2017: Reduced Incidence and Predictive Factors

Alessandra Di Francesco, MD, Andrea Bacigalupo, MD

Blood (2019) 134 (Supplement_1): 4526.

https://doi.org/10.1182/blood-2019-124843

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies

Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model

Altered Iron Parameters and Hepcidin Levels in a General Population: Lessons from the CHRIS Study

Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks

Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

ACUTE GRAFT Versus Host Disease 1990-2017: Reduced Incidence and Predictive Factors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only